Slater Vecchio has filed a lawsuit concerning the ineffectiveness of phenylephrine as a decongestant in certain cold, flu and allergy medication when consumed in tablet form.
On September 12, 2023, an independent advisory committee to the United States’ Food and Drug Administration (the “FDA”) announced that its members unanimously agreed that phenylephrine, an ingredient commonly found in over-the-counter cold/flu and allergy medications, is ineffective as a nasal decongestant when taken in tablet form.
The FDA’s committee explained that phenylephrine, when consumed in tablet form, metabolizes rapidly in the gut once ingested, allowing only a fraction of the phenylephrine consumed to reach the consumer’s nose and provide the represented medicinal benefits.
Slater Vecchio has filed an Application for Authorization in Quebec and Notice of Civil Claim in British Columbia.
All persons in Canada who purchased a cough medicine listed below:
If you have purchased one or more products containing phenylephrine listed above, please reach out to us by filling in the form on this webpage.
A class action is a legal case through which one person makes a claim to the Court on behalf of a similarly situated class of people who have the same or a similar legal claim. A class action seeks to hold a defendant or defendants responsible for their conduct that affects each member of the class by resolving issues that are common to the class in the same legal proceeding, instead of each class member bringing a claim individually.
The individual who first files the claim must ask the Court for permission to proceed as a class action. If permission is granted (referred as “authorized” in Quebec, and “certified” in all other Canadian provinces) and the case may proceed as a class action, the Court will appoint an individual as “Representative Plaintiff” to represent the best interests of the class during the litigation and will define the class group. Each person who meets the criteria of the class group is considered a “Class Member”.
